- Home
- MNDO vs GANX Comparison
MNDO vs GANX Comparison
Compare MNDO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- GANX
- Stock Information
- Founded
- MNDO 1995
- GANX 2017
- Country
- MNDO Israel
- GANX United States
- Employees
- MNDO N/A
- GANX N/A
- Industry
- MNDO EDP Services
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- GANX Health Care
- Exchange
- MNDO Nasdaq
- GANX Nasdaq
- Market Cap
- MNDO 39.9M
- GANX 41.9M
- IPO Year
- MNDO 2000
- GANX 2021
- Fundamental
- Price
- MNDO $2.10
- GANX $2.27
- Analyst Decision
- MNDO
- GANX Strong Buy
- Analyst Count
- MNDO 0
- GANX 5
- Target Price
- MNDO N/A
- GANX $7.60
- AVG Volume (30 Days)
- MNDO 46.8K
- GANX 218.6K
- Earning Date
- MNDO 03-05-2025
- GANX 03-25-2025
- Dividend Yield
- MNDO 11.43%
- GANX N/A
- EPS Growth
- MNDO N/A
- GANX N/A
- EPS
- MNDO 0.23
- GANX N/A
- Revenue
- MNDO $21,856,000.00
- GANX N/A
- Revenue This Year
- MNDO N/A
- GANX N/A
- Revenue Next Year
- MNDO N/A
- GANX N/A
- P/E Ratio
- MNDO $9.13
- GANX N/A
- Revenue Growth
- MNDO 2.27
- GANX N/A
- 52 Week Low
- MNDO $1.70
- GANX $0.89
- 52 Week High
- MNDO $2.28
- GANX $5.19
- Technical
- Relative Strength Index (RSI)
- MNDO 56.56
- GANX 47.71
- Support Level
- MNDO $2.07
- GANX $2.30
- Resistance Level
- MNDO $2.13
- GANX $2.81
- Average True Range (ATR)
- MNDO 0.05
- GANX 0.25
- MACD
- MNDO 0.00
- GANX -0.03
- Stochastic Oscillator
- MNDO 78.57
- GANX 35.33
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.